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initial PO dose was 0.08 mg/kg (range 0.04-0.18) and the median
conversion ratio was 0.26 (range 0.12-0.4). Median initial tacroli-
mus level after conversion was 16.9 ng/mL (range 5.3-52.4).
Twenty-seven patients (93%) required a reduction in their PO
dosing, only two patients immediately achieved a stable PO dose
(deﬁned as two consecutive tacrolimus levels within the therapeutic
range). Nine patients (31%) developed a creatinine level greater
than twice their baseline level, eleven patients (38%) required
intervention to lower potassium, and three patients (10%) devel-
oped tremors. No irreversible complications were encountered.
We conclude that the presently recommended conversion rate
frequently results in toxic serum levels associated with mild renal
insufﬁciency and other adverse effects. We have changed our
conversion rate from 1:4 to 1:2.
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PEDIATRIC PATIENTS BENEFIT FROM INTRAVENOUS BUSULFAN FOR
MYELOABLATION IN ALLOGENEIC HSCT
Fisher, V.L., Nieder, M.L., Malbassi, C., Halliday, E.R., Wiersma,
S.R., Reed, M. Rainbow Babies and Children’s Hospital/Case Western
Reserve University School of Medicine, Cleveland, OH
Oral busulfan is a component of standard preparative regimens
used for myeloablation in HSCT. In children, complications of
oral administration include emesis, frequent need for NG tube
insertion and irritability because of food restriction around the
time of dose administration. Plasma levels must be monitored, and
are often unpredictable, resulting in the need to adjust doses and
repeat levels. We administered intravenous busulfan to eleven
children (aged 9 months to 15 years) who were undergoing HSCT
(cord, marrow PBSC) for malignant and non-malignant disorders.
Patients received IV busulfan according to the following protocol:
Intravenous busulfan was diluted in D5W or NS to a ﬁnal con-
centration of 0.5mg/ml. Busulfan is stable for 8 hours at room
temperature or up to 12 hours (in NS only) at 2-8 degrees celsius.
The IV tubing was primed with the busulfan solution and admin-
istered through a controlled-rate infusion pump. It was infused
over 2 hours. Pharmacokinetic (PK) sampling was obtained after
the ﬁrst dose at 2,3,4,5 6 hours.When PK information was needed
after subsequent doses, a baseline level was obtained just prior to
the infusion of the next dose. Pharmacokinetic evaluations were
performed after the ﬁrst dose on all patients and after dose 9 on
seven patients. Based on the Dose 1 results, adjustments were made
for only 3 of 11 patients. Patients received oral or IV ondansetron
and no emesis was reported for any of the 11 patients. No toxicities
were observed on any patients during the four day administration
of the IV busulfan. One patient died of sepsis on Day T 11; all
other patients engrafted. Except for moderate VOD in one patient,
no unexpected GVHD, relapse or other acute toxicities were ob-
served. For children undergoing HSCT, IV busulfan is easier to
administer, is more acceptable to patients and their families, pro-
vides more predictable plasma levels and is not associated with
more acute toxicity than oral busulfan. When busulfan is used at
our institution, the intravenous form has become the standard
preparation for children less than 18 years of age.
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SUCCESSFUL USE OF ORAL TACROLIMUS FOR GVH PROPHYLAXIS
DURING THE FIRST 100 DAYS POST HSCT
Nieder, M.L., Fisher, V.L., Danish, D., Halliday, E.M., Wiersma, S.R.
Rainbow Babies and Children’s Hospital/Case Western Reserve Univer-
sity School of Medicine, Cleveland, OH
Traditionally, intravenous cyclosporine or tacrolimus has been
used in the early post-transplant period for GVH prophylaxis. We
report on the use of oral tacrolimus on sixteen patients (aged 15
months to 18 years) who underwent allogeneic stem cell trans-
plants (cord, PBSC marrow) for a variety of malignant and non-
malignant disorders. All patients received oral glutamine (2
grams/m2 per dose BID) beginning on T -5. Day T -2 through T
100, patients received tacrolimus (0.1-0.2 mg/kg dose BID)
orally or via an NG tube. For small children, our hospital phar-
macy produced a tracolimus suspension. Trough tacrolimus blood
levels were obtained 12 hours after the 4th dose and ranged from
6-14.3 ng/mL. Dose adjustments were made when necessary and
14 of 16 patients completely avoided intravenous tacrolimus. Two
patients required IV tacrolimus for 4-6 days in total because of
persistent vomiting. Avoiding the use of IV tacrolimus reduced the
need for additional IV access, resulted in less hypertension and
signiﬁcantly decreased the cost of the transplant. We observed no
increase in graft failure, GVH, infections, relapse or mortality.
Renal tubular acidosis is commonly seen in these patients, who
often require oral sodium bicarbonate supplemenation. For 14/16
patients, renal tubular function returned to normal within 3
months after stopping the tacrolimus. Oral tacrolimus can safely be
given to transplant patients from the beginning of the transplant
and throughout the ﬁrst 100 days post-transplant.
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NAUSEA AND VOMITING IN PATIENTS RECEIVING HIGH DOSE CHEMO-
THERAPY FOLLOWED BY PERIPHERAL BLOOD STEM CELL TRANS-
PLANT IN AN OUTPATIENT SETTING
Paivanas, N.1, Malone, C.1, Spiros, A.R.1, Sheridan, M.J.2, Spira,
A.I.1, Orloff, G.J.1, Beveridge, R.A.1 1. Fairfax Stem Cell Transplant
Program INOVA Fairfax Hospital Cancer Center, Fairfax, VA; 2.
INOVA Fairfax Hospital, Fairfax, VA
Background: Nausea and vomiting (N/V) are signiﬁcant side
effects in patients receiving high-dose chemotherapy therapy
(HDC). We examined our institution’s experience with N/V, as
presented in HDC patients receiving peripheral blood stem cell
transplants (PBSCT) utilizing 3 speciﬁc conditioning regimens.
Methods: A retrospective chart review was conducted on twenty-
nine patients who received an autologous PBSCT within the past
two years. Data was gathered from a daily nursing N/V assessment
Table.
Age Diagnosis PREP
ANC > 500
on T 
Serious
Adverse
Events
15 CML Bu-Cy 12 None
13 Sickle Cell Bu-Cy-ATG 20 None
0.11 HLH Bu-Cy-VP-ATG 13 Sepsis
15 AML-CR1 Bu-Cy 15 Mild VOD
0.10 AML-CR1 Bu-Cy 16 Mod VOD
4 Osteopetrosis Bu-Cy 15 None
2 AML-CR1 Bu-Cy 11 None
2 Beta Thal Bu-Cy 17 None
13 Beta Thal Bu-Cy None Sepsis/Death
0.9 MDS Bu-Cy 13 None
8 Neutropenia Bu-Cy 15 None
Table. Patient Demographics
Age in
Years Diagnosis PREP
Acute
GVH
HSC
Source
Status at
Day 100
18 ALL-CR3 ARAC-Cy-TBI II MUD-PB Alive; Relapse
0.9 MDS Bu-Cy None MRD-BM Alive & Well
18 ALL-CR2 Cy-TBI None MUD-PB Alive; Graft
Failure
5 ALL-CR2 Cy-TBI None MRD-UCB Alive & Well
18 ALL-CR3 Cy-TBI II MUD-PB Alive & Well
14 ALL-CR1 ARAC-Cy-TBI None MUD-BM Alive & Well
2 Beta Thal Bu-Cy None MRD-BM Alive & Well
15 CML Bu-Cy None MRD-BM Alive & Well
8 ALL-CR1 Cy-TBI None MUD-PB Alive & Well
4 Osteopetrosis Bu-Cy None MRD-BM Alive & Well
12 CML Cy-TBI None MRD-PB Alive & Well
18 Severe AA Cy-ATG II MRD-PB Alive & Well
1 AML-CR1 Cy-TBI None MRD-PB Alive; Relapse
8 Neutropenia Bu-Cy None MUD-PB Alive & Well
8 ALL-CR1 Cy-TBI II MRD-PB Alive & Well
13 Beta Thal Bu-Cy NA MRD-BM Deceased
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tool and extrapolated into N/V levels as: grade A (none to mild
nausea; no emesis recorded), grade B (moderate nausea; no emesis
recorded), or grade C (moderate nausea for more than half the
time, or any severe nausea or any emesis). Lorazepam and dolas-
etron were used prophylacticly from beginning of chemotherapy
through day1. Oral prochlorperazine was given prn. Results: 23
of 29 of patients experienced Grade A N/V during conditioning-
reinfusion phase. All patients received anti-emetic irrespective of
N/V grade. During Day 1 to Day 10, 13 of 29 patients expe-
rienced no higher than Grade A N/V, with 8 of those 13 requiring
anti-emetics. During Day 11 to Day 14, 19 of 29 had Grade A
N/V with 3 of those 19 requiring anti-emetics. A higher percent-
age (50%) of melphalan patients experienced Grade C N/V than
with BEAC (16%) or CBV (20%) in the third phase. 1 melphalan
patient and 1 BEAC patient required dronabinol to control per-
sistent N/V. Conclusions: Melphalan appears to cause more se-
vere and more delayed/extended N/V than BEAC or CBV. Pa-
tients receiving melphalan appeared signiﬁcantly less likely to
progress through PBSCT without receiving any anti-emetics.
While more patients are required to strengthen statistical signiﬁ-
cance, we believe these ﬁndings are predictive of N/V associated
with these three conditioning regimens. Further study should as-
certain improved approaches to N/V assessment and management.
250
A RETROSPECTIVE ANALYSIS OF HOSPITAL ADMISSIONS IN AN OUT-
PATIENT STEM CELL TRANSPLANT FACILITY
Malone, C., Paivanas, N., Spiros, A.R., Spira, A.I., Orloff, G.J.,
Beveridge, R.A. Fairfax Stem Cell Transplant Program INOVA Fair-
fax Hospital Cancer Center, Fairfax, VA
Methods: A retrospective chart review was conducted on 49
patients receiving autologous stem cell transplants in the outpa-
tient setting within a three year time frame. The patients were
transplanted for multiple myeloma (MM), Hodgkin’s lymphoma
(HD), or Non-Hodgkin’s lymphoma (NHL). The analysis consid-
ered: age at transplant, past medical history, disease status at
transplant, and outcomes of pretesting, to determine what charac-
teristics might predispose for hospital admission. Results: Thir-
teen patients were admitted from the outpatient setting, 8 for
sepsis/neutropenic fever, 3 for dehydration or vomiting, 1 for
mental status changes, and one for cardiac failure. Of the 13
(thirteen) patients requiring hospital admission, 12 had a disease
status at time of transplant of partial remission (PR), 1 (with 3 prior
relapses) was in complete remission (CR) prior to PBSCT. One
patient was admitted after white blood cell engraftment and one
admitted during chemotherapy administration. Of the patients not
requiring hospital admission from the outpatient setting, 14 were
PR, 16 were CR, 5 were relapsed with chemosensitive disease, and
1 was Rel1 (ﬁrst relapse after a CR). In the chart review, no
statistical correlations were found between the admitted and non-
admitted groups for: age, past medical history, and pretest indica-
tors. Conclusions: Patients with MM had a higher rate of hospital
admission from the outpatient setting versus those with either HD
or NHL. The incidence of hospitalization seems to be especially
prevalent in patients whose disease processes were not in complete
remission. This analysis suggests a correlation of disease and pre-
transplant status as a predictor of hospital admission; however,
further study is indicated.
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SAFETY AND TOLERABILITY OF COMBINATION ANIDULAFUNGIN
(ANID) AND LIPOSOMAL AMPHOTERICN B (LAMB) FOR THE TREAT-
MENT OF INVASIVE ASPERGILLOSIS (IA)
Herbrecht, R.1, Graham, D.2, Schuster, M.3, Henkel, T.4, Krause, D.4,
Schranz, J.4, Garbino, J.5, Caillot, D.6, Reinhardt, J.7, Maertens, J.8 1.
Departement d’Hematologie et d’Oncologie, Hopital de Hautepierre,
Strasbourg, France; 2. Springﬁeld Clinic Research, Springﬁeld, IL; 3.
University of Pennsylvania, Infectious Disease Division, Philadelphia,
PA; 4. Vicuron Pharmaceuticals, King of Prussia, PA; 5. Geneva Uni-
versity Hospital, Infectious Diseases, Switzerland; 6. Haematologique
Clinique, Hopital Bocage, CHU Dijon, France; 7. Christiana Care
Health Services, Infectious Disease Clinical Studies Research Institute,
Newark; 8. University Hospital, Herestraat 49, Department Pathophys-
iology, Leuven, Belgium
Background: Response rates with existing monotherapy for IA
remain suboptimal, and mortality remains unacceptably high.
Anidulafungin is a novel echinocandin (EC) in late stage develop-
ment with potent in vitro activity that is additive or synergistic with
amphotericin B (AmB) against Aspergillus spp. ANID’s distinct PK
characteristics and favorable safety proﬁle support development as
a ﬁrst-line therapeutic agent. AmB has efﬁcacy for IA but has
unacceptable toxicity. Combination of ANID and LAmB may offer
improved outcome with no excessive toxicity. The safety of com-
bination ANID plus LAmB was evaluated. Methods: Pts  18 yrs
with proven or probable IA (per EORTC, MSG criteria) and life
expectancy  72 hrs were enrolled into an open-label, non-com-
parative study. Exclusion criteria included receipt of more than 5
days of antifungal therapy (unless treatment failure) and AST/
ALT 5 X ULN. ANID was given as 200 mg IV loading dose day
1 with 100 mg daily maintenance (200/100mg); LAmB was given
daily up to 5 mg/kg/day. Treatment continued until resolution of
signs/symptoms up to 90 days. Clinical assessments were done on
therapy, end of therapy (EOT) and at 4 weeks post EOT (FU).
Safety labs and ECGs were performed. Results: Data on 17 of 30
enrolled patients are presented. Mean age was 55 (range 21-79).
The majority of pts had pulmonary IA (12); other sites included
CNS (2), cutaneous, hepatic and bone (1 each). Risk factors for IA
were steroid use (3); AML (3); ALL (1); other malignancies (2);
aplastic anemia (1) and other malignancies (2); allogeneic BMT (3);
heart (1) or liver transplant (1). 12 of 17 patients had at least 1
drug-related adverse event (DRAE). Of these pts, 7 and 3 had an
AE expected with LAmB and with LAmB and/or ANID, respec-
tively. DRAEs reported in  2 pts were hypokalemia, increased
transaminases, increased ALP, hypomagnesemia and ﬂushing. 14
pts had a total of 22 serious AEs; only 2 were drug related (renal
failure, an expected event for LAmB; abnormal LFTs). There were
9 deaths during the 90 day study period; none considered related to
study drug. No trends attributable to ANID/LAmB were seen for
post-baseline hematology or chemistry results. Conclusions: The
patterns of AEs and laboratory abnormalities were not unexpected
for this ill population. No untoward safety ﬁndings were found.
Based upon available data, ANID and LAmB can be safely co-
administered.
Table. Patients Experiencing N/V by Grade by PBSCT Phase
Patients Grouped by Grade N/V per PBSCT Phase
Conditioning
Regimen
Level of
N/V
Conditioning-
Reinfusion
Day 7 to
Day 0 (% of
Patients)
Day 1
through Day
10 (% of
Patients)
Day 11
through Day
14 (% of
Patients)
Melphalan
(n  12)
Grade C 3 (25%) 6 (50%) 6 (50%)
Grade B 0 (0%) 2 (16%) 0 (0%)
Grade A 9 (75%) 4 (33%) 6 (50%)
BEAC
(n  12)
Grade C 1 (8%) 4 (33%) 2 (16%)
Grade B 0 (0%) 2 (16%) 0 (0%)
Grade A 11 (92%) 6 (50%) 10 (84%)
CBV
(n  5)
Grade C 2 (40%) 2 (40%) 1 (20%)
Grade B 0 (0%) 0 (0%) 1 (20%)
Grade A 3 (60%) 3 (60%) 3 (60%)
Table. Frequency of Hospitalization Among Disorders
Disease Patients Admitted Patients Not Admitted
MM (n  20) 9 (45.0%) 11 (55.0%)
HD (n  9) 2 (22.2%) 7 (77.8%)
NHL (n  20) 2 (10.0%) 18 (90.0%)
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